Founded in 2014 and located in the vibrant Medtech ecosystem in Montpellier, France, Sim&Cure is a digital start-up focused on improving neurovascular treatments of cerebral aneurysm with a proprietary software suite (Class IIa medical device with CE mark and FDA 510k cleared) that has already been used to treat more than 7,000 patients in 400+ hospitals.
Sim&Cure has won the prestigious i-Lab national contest twice in 2014 and 2015 and i-Nov in 2020,
The start-up is backed by the Seed Fund IT-Translation and Elaia Partners
Sim&Cure has established scientific and clinical collaborations with leading laboratories and hospitals around the world.
Sim&Cure opened a subsidiary in US (NY) in July 2019.
The company employs 50 people and anticipates a phase of strong growth.
The medical device software Sim&Size allows physicians to define their therapeutic strategy thanks to the different modules:
– FDsize for Flowdiverters
– IDisze for Intrasaccular devices
– STsize for Supporting stents
– FCsize for Framing coils.
Since 2020, Sim&Cure also provides a training platform Sim&Train based on 3D printing technology and an educational version of Sim&Size.
The Sim&Cure goal is to always develop more products to secure neurovascular treatment.
Company’s Keywords:
medical software, medical devices, patientspecific, startup, endovascular treatments, innovation, neurovascular
50
medical devices
4000000
Gmail, Google Apps, Microsoft Office 365, OpenSSL, Mobile Friendly, Google Font API, reCAPTCHA, Google Tag Manager, Apache, WordPress.org
2014